頁籤選單縮合
題 名 | Efficacy of Intravenous and Subcutaneous Erythropoietin in Patients on Hemodialysis and Continuous Ambulatory Peritoneal Dialysis=靜脈注射及皮下注射紅血球生成素應用於血液透析及腹膜透析病患之成效分析 |
---|---|
作 者 | 賴彬卿; 吳麥斯; 黃正誼; 黃秋錦; 呂美玲; | 書刊名 | 長庚醫學 |
卷 期 | 17:2 1994.06[民83.06] |
頁 次 | 頁105-112 |
分類號 | 415.816 |
關鍵詞 | Erythropoietin; Hemodialysis; CAPD; Uremia; |
語 文 | 英文(English) |
中文摘要 | 本文研究係針對54名血液透析病患及11名腹膜透析病患分成5組,第1,2組接受中等劑量150-180單位/公/週之紅血球生成素治療。第3,4及5組接受低劑量75-90單位/公斤/週之紅血球生成素治療。其中第1,4組經由皮下注射,而第2,3組經由靜脈注射。11名腹膜透析患者(第5組)則全部接受週一次之皮下注射治療。療效經由下列5點來評估:(1)先期反應比率(2)延遲反應比率(3)達到標的血球容積的時間(4)治療累積劑量(5)維持劑量。研究結果顯示:(1)劑量高低是決定效果出現的速度及病人反應程度的首要因素。(2)皮下注射比靜脈注射有效,其劑量可節省20-30%。(3)腹膜透析比血液透析患者對紅血球生成素的反應來得好。 |
英文摘要 | We carried out our study with 54 hemodialysis patients and 11 CAPD patients. The hemodialysis patients were divided into five groups. Group 1& group 2 received intermediate doses of erythropoietin ranging from 150 U/Kg/wk to 180 U/Kg/wk. Group 3, group 4 and group 5 received low doses of erythropoietin ranging from 75 U/Kg/wk to 90 U/Kg/wk. While group 1& group 4 received erythropoietin subcutaneously, group 2& group 3 received erythropoietin intravenously. The CAPD patients all received subcutaneous erythropoietin. The efficacy of the erythropoietin therapy was evaluated by (1) the early response rate, (2) the late response rate, (3) the time to reach the target hematorcrit, (4) the therapeutic cumulative dose, and (5) the maintenance dose. We concluded that: (1) dose is the prime factor determining the rate and ratio of patients response to erythropoietin. (2) subcutaneous administration is more effective than the intravenous route resulting in a 20% to 30% dose-reduction effect, and (3) CAPD patients had a better erythropoietin response than the hemodialysis patients. A larger study is necessary to confirm this finding. |
本系統中英文摘要資訊取自各篇刊載內容。